Acorda to buy Civitas

Acorda Therapeutics Inc. (Nasdaq: ACOR) will pay approximately $525 million in cash to acquire Civitas Therapeutics. Shares of the biopharmaceutical leaped $5.64 to $34.99.


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.